- Gabrielius Misurenkovas, a 12-year-old boy with the rare, painful skin condition, recessive dystrophic epidermolysis bullosa (RDEB), has gained more freedom thanks to a new clinical trial.
- RDEB causes extremely fragile skin, leading to blistering, deep wounds, and scarring, with only around 150 children in the UK affected and no prior specific treatment available.
- Gabrielius participated in a clinical trial at Great Ormond Street Hospital and Birmingham Children’s Hospital, receiving intravenous infusions of mesenchymal stromal cells (MSC), specifically CORDStrom.
- The trial significantly improved his condition, leading to quicker wound healing, reduced inflammation and itchiness, and allowing him to participate in activities like playing football and cycling.
- The company INmuneBio is providing CORDStrom free for a year to trial participants and is seeking regulatory approval for the treatment in the UK and other countries.
IN FULL